Navamedic ASA, 30 October 2019: Reference is made to the previous stock exchange
notices made by Navamedic ASA (the "Company" or "NAVA") on 19 June 2019 and 5
August 2019 regarding the demerger of NAVA, whereby inter alia the Company's
Medtech division is demerged from NAVA and merged into Observe Medical ASA
("Observe Medical"), which will be listed on Oslo Axess following completion of
the demerger.
As announced by Oslo Børs, the board of directors of Oslo Børs has today
approved the listing of the shares in Observe Medical on Oslo Axess, subject to
fulfilment of the listing requirements on Oslo Axess which will be fulfilled
upon completion of the demerger of NAVA and the publication of a listing
prospectus.
The completion of the demerger is expected to be registered with the Norwegian
Register of Business Enterprises (Nw. Foretaksregisteret) following close of
trading on Oslo Børs on 31 October 2019.
Below are key dates related to the completion of the demerger of the Company and
listing of the shares of Observe Medical on Oslo Axess:
* Last day of trading in the NAVA shares inclusive of right to demerger
consideration in the form of consideration shares in Observe Medical (cut-off
date): 31 October 2019
* Registration of the completion of the demerger with the Norwegian Register of
Business Enterprises: 31 October 2019 (after close of trading)
* First day of trading in the NAVA shares exclusive of right to consideration
shares as demerger consideration: 1 November 2019
* Registration of share capital increase of NOK 832,000 in Observe Medical by
issuance of 3,200,000 new shares each with a nominal value of NOK 0.26 to NAVA
following completion of debt conversion in Observe Medical: 1 November 2019
* First day of trading in the Observe Medical shares on Oslo Axess: 4 November
2019
* Record date (*): 4 November 2019
* Delivery of the Observe Medical consideration shares to eligible shareholders'
VPS accounts: 5 November 2019
(*) Shareholders of NAVA as of the expiry of the cut-off date as registered in
NAVA's shareholders register with the VPS as of expiry of the record date, will
receive one consideration share in Observe Medical for each share they own in
NAVA as of expiry of the cut-off date as recorded with the VPS on the record
date.
Trading in the Observe Medical shares will commence prior to delivery of such
shares to eligible shareholders' VPS accounts. Trades during this period until
delivery of the shares to eligible shareholders' VPS accounts will be settled on
a T+2 basis. No account-to-account transactions and no transactions with
settlement prior to 5 November 2019 will be allowed in this period.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Toril Ås, CFO, Navamedic
Mobile: +47 957 01 071
E-mail: toril.as@navamedic.com
About Navamedic ASA:
Navamedic ASA is a preferred, full-service provider of high-quality healthcare
products to hospitals and pharmacies. Navamedic meets the specific medical needs
of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com.